Results from Mont Blanc Phase 3 Trial of Nicox's NCX 470 in Glaucoma Published in the American Journal of Ophthalmology [Yahoo! Finance]
Bausch + Lomb Corporation (BLCO)
Company Research
Source: Yahoo! Finance
First publication of the data from the Mont Blanc Phase 3 trial in a peer-reviewed journal Authors conclude: "NCX 470 could become an important first-line therapy for IOP reduction in glaucoma." Topline results from second Phase 3 trial of NCX 470, Denali, expected in H2 2025 March 20, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the results from the Mont Blanc pivotal Phase 3 trial comparing NCX 470 to latanoprost in the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension have been published in the peer-reviewed journal American Journal of Ophthalmology. The principal author of the publication is Dr. Robert Fechtner, Professor and Chair of the Department of Ophthalmology at SUNY Upstate Medical University, Syracuse, NY and Chairman of Nicox's U.S. Glaucoma Clinical Advisory Board. “ We are pleased to
Show less
Read more
Impact Snapshot
Event Time:
BLCO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLCO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLCO alerts
High impacting Bausch + Lomb Corporation news events
Weekly update
A roundup of the hottest topics
BLCO
News
- Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes [Yahoo! Finance]Yahoo! Finance
- Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry EyesBusiness Wire
- Bausch + Lomb Co. (NYSE: BLCO) had its price target lowered by analysts at Royal Bank of Canada from $20.00 to $18.00. They now have an "outperform" rating on the stock.MarketBeat
- Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs [Yahoo! Finance]Yahoo! Finance
BLCO
Earnings
- 2/21/24 - Beat
BLCO
Sec Filings
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- 4/2/24 - Form 4
- BLCO's page on the SEC website